ライフサイエンスコーパス: periodontal therapy

1 before and after completion of non-surgical periodontal therapy.

2 (n = 20) included patients who did not have periodontal therapy.

3 ccess needs after completion of non-surgical periodontal therapy.

4 essure and subclinical atherosclerosis after periodontal therapy.

5 al disease in smokers remains a challenge of periodontal therapy.

6 Serum analytes were not influenced by periodontal therapy.

7 raphic indicators of bone regeneration after periodontal therapy.

8 matrix derivative (EMD) is commonly used in periodontal therapy.

9 ment of gingival condition and changes after periodontal therapy.

10 of D-ROM (P < 0.01) were observed following periodontal therapy.

11 nd did not undergo resective or regenerative periodontal therapy.

12 enzyme inhibitors or receptor antagonists in periodontal therapy.

13 periodontitis before and after non-surgical periodontal therapy.

14 loss, are the actual and desired outcomes of periodontal therapy.

15 icient calculus removal is a primary goal in periodontal therapy.

16 s in practice, and referral for non-surgical periodontal therapy.

17 f depression on their patients' responses to periodontal therapy.

18 ma denticola before and following mechanical periodontal therapy.

19 n patients usually not receiving concomitant periodontal therapy.

20 cerns about medications as a risk factor for periodontal therapy.

21 ion of migrated teeth sometimes occurs after periodontal therapy.

22 is often the motivation for patients to seek periodontal therapy.

23 delivery of a standard non-surgical phase of periodontal therapy.

24 attachment compared to non-smokers following periodontal therapy.

25 ts represents a unique treatment approach in periodontal therapy.

26 mos after delivery of standard non-surgical periodontal therapy.

27 trends in referral patterns of patients for periodontal therapy.

28 tigated further for possible development for periodontal therapy.

29 monitored before and up to 5 years following periodontal therapy.

30 le-dose drug delivery systems appropriate to periodontal therapy.

31 to and at 3, 6, 12, 24, and 36 months after periodontal therapy.

32 in assessing disease status and response to periodontal therapy.

33 teroid therapy as an adjunct to non-surgical periodontal therapy.

34 regard it as osteoinductive when utilized in periodontal therapy.

35 odontal healing in barrier membrane-assisted periodontal therapy.

36 th EB present a unique challenge in terms of periodontal therapy.

37 urgical treatment and a period of supportive periodontal therapy.

38 inical outcomes of non-surgical and surgical periodontal therapy.

39 uate the effect of smoking on the outcome of periodontal therapy.

40 ant role in achieving a desirable outcome in periodontal therapy.

41 ing used clinically than any other agents in periodontal therapy.

42 ATV or placebo gels as adjunct to mechanical periodontal therapy.

43 s remaining after completion of non-surgical periodontal therapy.

44 e of Gram-negative bacteria before and after periodontal therapy.

45 periodontitis were treated with non-surgical periodontal therapy.

46 Periodontitis patients received non-surgical periodontal therapy.

47 patients are more compliant with supportive periodontal therapy.

48 line and at the first and third months after periodontal therapy.

49 of furcation defects is a core component of periodontal therapy.

50 djunct to resective or regenerative surgical periodontal therapy.

51 defects is an important therapeutic goal of periodontal therapy.

52 ver (FMF) and their response to non-surgical periodontal therapy.

53 quires effective endodontic and regenerative periodontal therapy.

54 ts to be initially treated with non-surgical periodontal therapy.

55 onization of flora may affect the outcome of periodontal therapy.

56 -1 genotypes on the outcomes of non-surgical periodontal therapy.

57 periodontitis before and after non-surgical periodontal therapy.

58 erapy (PDT) as monotherapy during supportive periodontal therapy.

59 tors of poor response following non-surgical periodontal therapy.

60 at baseline and 3 months after non-surgical periodontal therapy.

61 received an intensive course of non-surgical periodontal therapy.

62 on periodontitis progression and response to periodontal therapy.

63 nts responding poorly to mechanical forms of periodontal therapy.

64 esponse in LAP can be partially modulated by periodontal therapy.

65 ity of periodontal disease and the effect of periodontal therapy.

66 and six oral antibiotics of potential use in periodontal therapy.

67 critical to optimize the results of surgical periodontal therapy.

68 otics are emerging as a promising adjunctive periodontal therapy.

69 t and control sites as an adjunct to Phase 1 periodontal therapy.

70 t was treated with non-surgical and surgical periodontal therapies.

71 iscuss strategies for future applications in periodontal therapies.

72 is, randomly assigned into test group (basic periodontal therapy + 0.12% chlorhexidine) with 61 impla

73 cations used after surgical and non-surgical periodontal therapy (4-week period).

74 ects with above average clinical response to periodontal therapy after correction for possible confou

75 or alveolar bone compared with conventional periodontal therapy alone.

76 ficantly reduced 3 months after non-surgical periodontal therapy, although they never reached the sam

77 ation lesions are a challenging scenario for periodontal therapy and a serious threat for tooth progn

78 mination and PRA were performed after active periodontal therapy and after 3 years of PMT.

79 rous and insightful look into the origins of periodontal therapy and anesthesia in "Happy Memories of

80 ria reduction process, it was suggested that periodontal therapy and chlorhexidine (CHX) rinse could

81 dontal disease before and after non-surgical periodontal therapy and correlate these values with clin

82 mproves the clinical outcome of non-surgical periodontal therapy and may be an appropriate adjunctive

83 dy is to evaluate the effect of non-surgical periodontal therapy and medical treatment on the level o

84 Healing following initial periodontal therapy and osseous periodontal surgery occu

85 Non-surgical periodontal therapy and periodontal disease severity wer

86 Smokers have a diminished response to periodontal therapy and show approximately half as much

87 Following nonsurgical periodontal therapy and smoking cessation, the subgingiv

88 iologic effects of a two-phase antimicrobial periodontal therapy and tested microbiologic, clinical,

89 Patients with GAgP received non-surgical periodontal therapy and were followed for 6 months.

90 vercome limitations associated with existing periodontal therapies, and may provide a new direction i

91 nce of periodontal disease, poor response to periodontal therapy, and a high risk for developing head

92 ical and radiographic response to mechanical periodontal therapy, and assess the factors associated w

93 etween host-parasite interaction, outcome of periodontal therapy, and systemic factors is best repres

94 erties of tetracycline (TCN) are valuable in periodontal therapy, and TCN treatment can remove the sm

95 Care include tobacco cessation as a part of periodontal therapy, and the 2000 Surgeon General's Repo

96 pathologically migrated teeth after routine periodontal therapy, and to study the relation between t

97 ation involvement; non-surgical and surgical periodontal therapy; and reasons for tooth loss.

98 Periodontal treatment consists of active periodontal therapy (APT) and supportive periodontal the

99 postoperative care and subsequent supportive periodontal therapy are essential to achieve sustainable

100 ied bone allograft (DFDBA) is widely used in periodontal therapy as a scaffold for new bone formation

101 Tetracyclines are used in periodontal therapy as antimicrobial agents and as inhib

102 Ts) consistently demonstrate that mechanical periodontal therapy associates with approximately a 0.4%

103 xidine oral rinse at baseline and supportive periodontal therapy at 3 and 6 months.

104 enhance the effectiveness of these agents in periodontal therapy by enhancing or sustaining their the

105 itis (good responders [GR]) before and after periodontal therapy by using the Human Oral Microbe Iden

106 Information on sociodemographics, periodontal therapy, calculus and plaque, number of rema

107 It also suggests that periodontal therapy can be performed successfully at sit

108 vious studies have suggested that success of periodontal therapy depends on the specific attachment,

109 Nonsurgical periodontal therapy did not improve glycemic control in

110 The NPC appreciates that periodontal therapy done by periodontists increases thei

111 tion with the use of lasers for non-surgical periodontal therapy due to ablation, vaporization, hemos

112 ontal Therapy [OPT] Study) demonstrated that periodontal therapy during pregnancy improved periodonta

113 ffect of intensive oral hygiene regimens and periodontal therapy during pregnancy on periodontal heal

114 minimum 12 months) with CP with non-surgical periodontal therapy either alone or associated with loca

115 In periodontal therapy enamel matrix derivative (EMD) has b

116 Regenerative periodontal therapy encompasses use of various bioactive

117 d better compliance than those without prior periodontal therapy experiences.

118 atients were treated with four modalities of periodontal therapy followed by supportive periodontal t

119 eatment and after completion of non-surgical periodontal therapy for 213 sextants in 38 patients by t

120 ived oral hygiene instruction and mechanical periodontal therapy for a period of 4 to 5 weeks.

121 Published RCTs including periodontal therapy for diabetic subjects, a metabolic o

122 Decisions in periodontal therapy for multirooted teeth are essentiall

123 cal role for smoking cessation counseling in periodontal therapy for smokers in order to effectively

124 uld improve clinical results of non-surgical periodontal therapy for smokers with chronic periodontit

125 of Glanzmann's thrombasthenia presented for periodontal therapy for spontaneous gingival hemorrhage.

126 At 6 months, mean HbA1c levels in the periodontal therapy group increased 0.17% (SD, 1.0), com

127 terns of SAEs indicated that subjects in the periodontal therapy group tended to be less likely to ex

128 Non-surgical periodontal therapy had a beneficial effect on the signs

129 Although periodontal therapy has been shown to be safe and leads

130 However, its influence on periodontal therapy has not been clearly determined.

131 sive techniques in non-surgical and surgical periodontal therapy has not progressed to the same exten

132 namel matrix protein derivative (EMD) during periodontal therapy have been shown to be safe for the p

133 growing interest in the use of probiotics in periodontal therapy; however, until now, most research h

134 Periodontal therapy improved clinical and microbiologic

135 Likewise, recent non-smokers respond to periodontal therapy in a manner similar to patients who

136 nhance the clinical benefits of non-surgical periodontal therapy in adults who are otherwise healthy.

137 s would improve the response to non-surgical periodontal therapy in obese patients.

138 e to conduct a secondary prevention trial of periodontal therapy in patients who have had coronary he

139 biotic supplementation adjunctive to initial periodontal therapy in patients with chronic periodontit

140 Initial periodontal therapy in patients with COPD with CP may de

141 10, 1 month, and 3 months following initial periodontal therapy in patients with CP.

142 on clinical response following non-surgical periodontal therapy in patients with severe periodontiti

143 polymorphisms are associated with success of periodontal therapy in pregnant women with periodontal d

144 e evidence suggesting a negligible effect of periodontal therapy in reducing interleukin-6 and lipids

145 microbials improved efficacy of non-surgical periodontal therapy in reducing PD and improving CAL at

146 th SRP improves the efficacy of non-surgical periodontal therapy in reducing probing depth and improv

147 t reduction in HbA1c observed as a result of periodontal therapy in subjects with type 2 diabetes is

148 statistically significant improvement after periodontal therapy in the BS compared with the obese gr

149 nct to SRP to provide a new dimension in the periodontal therapy in the near future.

150 This report proves the efficiency of periodontal therapy in the prevention of future periodon

151 ary or even justified to evaluate effects of periodontal therapy in these defects, and can be substit

152 rant secretion of chemerin, and non-surgical periodontal therapy influenced the decrease of GCF cheme

153 it mouth study evaluated a new model to test periodontal therapy involving a novel bioerodible copoly

154 d the impact of standard (SPT) and intensive periodontal therapy (IPT) on serum inflammatory markers

155 ological response of smokers to non-surgical periodontal therapy is compared to non-smokers.

156 Long-term evaluation of periodontal therapy is important for clinical decision m

157 tion of whether the additional use of EMD in periodontal therapy is more effective compared with a co

158 An improved response to non-surgical periodontal therapy is observed in obese patients who ha

159 lized freeze-dried bone allograft (DFDBA) in periodontal therapy is widely accepted.

160 Mechanical periodontal therapy is widely used for a variety of peri

161 modulation of host inflammatory response in periodontal therapy, it is important to control the bact

162 of patients with periodontitis submitted to periodontal therapy/maintenance and implant placement.

163 These findings suggest that non-surgical periodontal therapy may be associated with a substantial

164 Initial periodontal therapy may be helpful for diminishing oxida

165 ies suggest that initial patient response to periodontal therapy may be related to emotional intellig

166 Limited evidence suggests that periodontal therapy may improve glycemic control.

167 The current study investigates whether periodontal therapy may reduce systemic inflammation in

168 Periodontal therapy may reduce these pathogens colonized

169 and oral hygiene instructions (n = 20) or no periodontal therapy (n = 20).

170 ed randomly to either a control group (C; no periodontal therapy) (n = 35) or an experimental group (

171 ilure or success 5 years after completion of periodontal therapy, none of the four strategies produce

172 ssess the short-term effects of non-surgical periodontal therapy (NSPT) on the gingival crevicular fl

173 d to evaluate the changes after non-surgical periodontal therapy (NSPT).

174 in-1, (b) limited evidence on the effects of periodontal therapy on arterial blood pressure, leucocyt

175 zithromycin in combination with non-surgical periodontal therapy on clinical and microbiologic parame

176 The effect of periodontal therapy on diabetes outcomes has not been es

177 authors aim to assess the effect of initial periodontal therapy on exacerbation frequency in COPD pa

178 ; and 3) evaluate the effect of non-surgical periodontal therapy on GCF chemerin levels.

179 dy was to examine the effect of non-surgical periodontal therapy on GCF levels of ICTP and IL-1.

180 vidence is available regarding the effect of periodontal therapy on major disease endpoints such as t

181 ect of two modes of delivery of non-surgical periodontal therapy on patient experience of pain and or

182 eriod of 6 months the effect of non-surgical periodontal therapy on serum levels of high-sensitivity

183 sulted in: (a) no evidence on the effects of periodontal therapy on subclinical atherosclerosis, seru

184 G, and to examine the effect of conservative periodontal therapy on these levels.

185 The effect of periodontal therapy on these systemic factors may be rel

186 All published trials included non-surgical periodontal therapy; only two included systemic antimicr

187 of women participating in the Obstetrics and Periodontal Therapy (OPT) Study.

188 A recent clinical trial (Obstetrics and Periodontal Therapy [OPT] Study) demonstrated that perio

189 levels of HbA1c, FPG, and CML, and improves periodontal therapy outcome in people with DMt2 and CP.

190 th factor (PDGF) have significantly enhanced periodontal therapy outcomes with a high degree of varia

191 mmunity dental care group reported receiving periodontal therapy outside of the study.

192 on of participants in this group may receive periodontal therapy outside of the study.

193 not differ between groups or during initial periodontal therapy (P >0.05).

194 _0.54, _0.19) compared to no treatment after periodontal therapy (p < 0.0001).

195 ) with 61 implants; and control group (basic periodontal therapy + placebo) with 58 implants.

196 l maintenance care, and completion of active periodontal therapy prior to October 1987.

197 ible participants were randomized to receive periodontal therapy provided by the study or community d

198 ied, intensive instructions and non-surgical periodontal therapy provided during 8 weeks at early pre

199 d discuss all published RCTs testing whether periodontal therapy reduces rates of preterm birth and l

200 systemic antibiotic usage, with non-surgical periodontal therapy resulted in improvement in clinical

201 lementation in conjunction with conventional periodontal therapy (scaling and root planing [SRP]) on

202 All participants received non-surgical periodontal therapy (scaling and root planing and oral h

203 All participants received non-surgical periodontal therapy (scaling and root planing).

204 fects of two different forms of non-surgical periodontal therapy, scaling and root planing (SRP) per

205 Non-surgical periodontal therapy, scaling and root planing, does not

206 Supportive periodontal therapy seemed to reduce the rate of occurre

207 Hence, regenerative periodontal therapy should be considered before resectiv

208 icillin plus metronidazole in the context of periodontal therapy should be limited to patients with s

209 In full-term and preterm women, periodontal therapy significantly reduced (P <0.01) coun

210 gnant women with periodontitis, non-surgical periodontal therapy significantly reduced levels of peri

211 lth" should be considered a true endpoint of periodontal therapy, since this outcome provides a condi

212 Following initial non-surgical periodontal therapy, sites were randomly selected to rec

213 Following non-surgical periodontal therapy, sites were randomly selected to rec

214 After periodontal therapy, sites with angular and horizontal a

215 tudy aims to assess compliance to supportive periodontal therapy (SPT) among patients treated with de

216 t the time of routinely scheduled supportive periodontal therapy (SPT) appointments by 2 evaluators.

217 in a group of patients undergoing supportive periodontal therapy (SPT).

218 ive periodontal therapy (APT) and supportive periodontal therapy (SPT).

219 and if results are substantiated, adjunctive periodontal therapies subsequently need to be evaluated.

220 d at 3 months following completion of active periodontal therapy supplemented by amoxicillin plus met

221 study assesses the differential outcomes of periodontal therapy supplemented with amoxicillin-metron

222 and 1.5, 3, and 6 months after non-surgical periodontal therapy: supra- and subgingival plaque from

223 ays) during the first, non-surgical phase of periodontal therapy (T1) and placebo during the second,

224 Following periodontal therapy, the leukocyte activity was signific

225 onsidered the gold standard for non-surgical periodontal therapy, then the evidence supporting laser-

226 as a multicenter, randomized trial comparing periodontal therapy to community dental care.

227 to the 3-month visit, and from completion of periodontal therapy to each annual visit up to the 5-yea

228 eplacement graft (BRG) materials are used in periodontal therapy to encourage new bone formation.

229 ceutical agents has been proposed for use in periodontal therapy to inhibit loss of alveolar bone and

230 SETTING, AND PARTICIPANTS: The Diabetes and Periodontal Therapy Trial (DPTT), a 6-month, single-mask

231 ontitis who participated in the Diabetes and Periodontal Therapy Trial (DPTT); and associations among

232 Periodontal therapy triggers a short-term inflammatory r

233 ects on both hard and soft tissues following periodontal therapy using a single statistical test.

234 compare disease progression and response to periodontal therapy using both individual site activity

235 Seven patients scheduled to undergo periodontal therapy utilizing non-absorbable membranes a

236 Periodontal therapy varied considerably.

237 to assess whether the degree of response to periodontal therapy was associated with changes in serol

238 Overall, periodontal therapy was found to be effective in improvi

239 Non-surgical and surgical periodontal therapy was performed, and the patient was p

240 itis and Vascular Events (PAVE) pilot study, periodontal therapy was provided as an intervention in a

241 Periodontal therapy was successful in reducing clinical

242 urther pilot intervention study of 14 cases (periodontal therapy) was performed.

243 GCF and a significant decrease after initial periodontal therapy were determined in the CP group (P <

244 to receive immediate or delayed non-surgical periodontal therapy were evaluated at baseline and 6 mon

245 egeneration in smokers and non-smokers after periodontal therapy were selected.

246 All patients underwent periodontal therapy, which consisted of full-mouth mecha

247 ed to have an impact on the ultimate goal of periodontal therapy, which is tooth retention.

248 tenance program and provided with supportive periodontal therapy with 3 to 4 appointments annually.

249 Long-term microbiologic outcomes of periodontal therapy with adjunctive antibiotics either i

250 is to evaluate the influence of non-surgical periodontal therapy with adjunctive systemic antibiotics

251 bout the protocol of choice for non-surgical periodontal therapy with adjuvant use are still reported

252 review if they reported outcomes of surgical periodontal therapy with and without the use of lasers.

253 clinical treatment outcomes of regenerative periodontal therapy with bone replacement grafts.

254 mly assigned to receive initial non-surgical periodontal therapy with scaling/root planing and oral h

255 l conditions in pregnant women, case-related periodontal therapy, with or without systemic antibiotic